Forgot your password ?




SICOT e-Newsletter

Issue No. 34 - July 2011 

  • SICOT Events
    - SICOT 2011 XXV Triennial World Congress - Prague, Czech Republic
  • SICOT News
    - 2011 AAOS/SICOT International Surgical Skills Scholarship Programme
    - European Musculoskeletal Review - Volume 6 Issue 2
  • Worldwide News
    - Current Concepts in Joint Replacement™ - Winter 2011 
    - Basic Training

 

Editorial by Cody Bünger, SICOT President

  • SICOT on the MOVE!

Universal Challenges in Orthopaedics

Musculoskeletal diseases and disability are a major societal burden worldwide affecting the lives of millions of people both in the developed and developing worlds. Every 30 seconds someone dies in a traffic accident and 20-30 million people worldwide are injured. Road traffic accidents are the leading cause of death and disability of people under the age of 45. Trauma patients need organised triage, damage control and multidisciplinary involvement along with sub-acute total repair. At the same time, the population is aging and osteoporosis is becoming a major health issue resulting in fragility of the bones leading to vertebral fractures and hip fractures. Diseases such as HIV, tuberculosis and cancer are frequent co-morbidities or primary diseases. Read more...

 


 

SICOT Events

SICOT 2011 XXV Triennial World Congress
6-9 September 2011 - Prague, Czech Republic

Please check the SICOT website regularly for updated information about Prague TWC 2011.

  • Scientific Programme 

The allocated presentation time during free paper sessions is six minutes, plus an extra two minutes for discussion. Please visit the SICOT website for any updates in the scientific programme.

The 'SICOT 2011 XXV Triennial World Congress' is designated for a maximum of (or 'for up to') 21 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Read more...

  • Registration

Due to high demand, online congress registration will be open here until 24 August! Avoid queuing on site and register now for the Congress!

As a SICOT member you can save money on your congress registration fee. If you are not already a member, click here to find out how you can join SICOT.

Special preferential membership dues are available for new members from our Friendship Nations: China, Belarus, Kazakhstan, Kyrgyzstan, Russia, Ukraine, and member countries of the Pan Arab Orthopaedic Association (PAOA). Click here to find out how you can join SICOT. Become a SICOT member and save money!

  • Plenary Speakers

We are pleased to announce that Christian Gerber (Switzerland), Pierre Hoffmeyer (Switzerland), Frédéric Picard (United Kingdom), and James Wright (Canada) will be delivering plenary lectures on various topics of interest during the Congress. Read more...

  • Presidential Speaker

Cody Bünger, SICOT President, will be delivering his Presidential Lecture at 10:00 on Wednesday, 7 September in the Forum Hall of the Prague Congress Centre.

  • Symposia

Click here for the full list of symposia which will take place during the Congress.

  • SICOT Educational Day 2011

The SICOT Educational Day is a new initiative undertaken by the SICOT Young Surgeons Committee. The aim of this day is to provide a comprehensive review course for residents and an evidence-based update for practicing surgeons on a specific theme at each SICOT meeting. The theme is selected in such a way that it is mutually beneficial to the residents in their exams and to the orthopaedic surgeons in their daily practice.

The theme chosen for this year is 'The Hip'. Great teachers from around the world are being brought together to lecture on their area of expertise. Read more... Registration is still possible until 24 August!

  • Instructional Courses

Click here to read more about the 17 Instructional Courses which will be held throughout the Congress. Registration is still possible until 24 August!

  • Social Programme

Register here for our attractive social programme which includes the Opening Ceremony/Welcome Reception, Fun Night, and Presidents' Dinner. Read more...

  • Sports Programme

The Charity Run will be held on Wednesday, 7 September at 06:30 (a morning run is the best way to start the day!) The funds collected will support orthopaedic treatment of children at SICOT Education Centres. Read more...

NEW! A Golf Tournament is being organised at the Konopiště Golf Resort on Friday, 9 September. Register here.

  • NEW! Cultural Programme

Tickets for "The Rite of Spring" (ballet), "Cosi fan tutte - Wolfgang Amadeus Mozart" (opera), "L'elisir d'amore - Gaetano Donizetti" (opera), and "Rusalka - Antonín Dvořák" (opera) are available to participants of the SICOT 2011 XXV Triennial World Congress.

More information about the cultural programme and how to book for the various events can be found here. 

  • Accommodation & Tours

Please don't delay booking your accommodation until the last minute! Prague is very busy in early September and suitable accommodation is quickly sold out. Special prices and benefits are available for congress participants. Book your accommodation here. 

  • Exhibition & Sponsorship

    Don't miss out on this unique opportunity to promote your products and services to leading international orthopaedic surgeons, traumatologists and specialists in related fields.

Exhibition & Sponsorship Prospectus (pdf)

If you are interested in sponsoring, exhibiting, or advertising at the Congress, please contact Lina Salvati:

Lina Salvati
Linsa Inc. (Canada)
 
Tel.: 1 514 924 3476
E-mail: lsalvati@linsa.ca  
Skype: ripley9423

 


 

SICOT News

  • 2011 AAOS/SICOT International Surgical Skills Scholarship Programme

The American Academy of Orthopaedic Surgeons (AAOS) is pleased to announce it is accepting applications for the 2011 AAOS/SICOT International Surgical Skills Scholarship Programme. Through a generous contribution from SICOT-USA, AAOS will award one scholarship to a SICOT member for the intended purpose to travel to the United States to attend a hands-on orthopaedic surgical skills course with cadaveric specimens in the Orthopaedic Learning Center in Rosemont, Illinois, USA. The scholarship visit also includes a 2-3 day observership at a high-volume USA hospital. The application deadline for the 2011 AAOS/SICOT-USA scholarship programme is: 9 September 2011. Application form - Read more...

  • European Musculoskeletal Review - Volume 6 Issue 2

As part of a media partnership with Touch Briefings, SICOT members receive free eBook access to European Musculoskeletal Review - Volume 6 Issue 2

In the latest issue Professor Xenofon Baraliakos et al. contribute an excellent paper, 'The Relationship of Biomarkers and Radiographic Progression in Patients with Ankylosing Spondylitis Treated with Infliximab', while Professor Salvatore Minisola discusses the pharmacological treatment of osteoporosis. Elsewhere in this edition, Professors Victor Valderrabano and Monika Horisberger provide a fascinating exploration of ankle osteoarthritis.

Directed by an Editorial Board comprising internationally respected physicians, European Musculoskeletal Review’s peer-reviewed articles endeavour to provide a concise and timely update on the latest opinion and advances spanning the breadth of musculoskeletal practice.

Click through to:
www.touchmusculoskeletal.com/content/european-musculoskeletal-review-volume-6-issue-2-contents

SICOT members access the current edition, European Musculoskeletal Review – Volume 6 issue 2, in full and for free in eBook format. Click here to access your complimentary eBook. (If you are a SICOT member, please log in to the SICOT website first with your username (member ID number/e-mail address) and password. Information about resetting passwords is available on the SICOT website.)

Fore more information please visit: www.touchmusculoskeletal.com/

 


 

SICOT Global Network for Electronic Learning - SIGNEL

  • Article of the Month

Use and efficacy of bone morphogenetic proteins in fracture healing
Suzanne N. Lissenberg-Thunnissen, David J. J. de Gorter, Cornelis F. M. Sier & Inger B. Schipper

Purpose This review evaluates the application of bone morphogenetic proteins (BMPs) in delayed bone repair, aiming at a broad audience from clinicians to scientists. Next to an overview of the role of the different BMPs, their antagonists and their current applications, special attention is focused on new scientific developments improving the effects of BMP-based therapy for bone repair. Read more...

  • Case of the Month

A 20-year-old young woman is referred to the orthopaedic department with a three-month history of pain in the right hip joint and buttock. It is aggravated by exercise but exists also at rest. She reports no trauma. Pain medication with Etoricoxib and Tramadol is ineffective.

Physical examination revealed bland skin conditions, a restricted ROM with moderate pain. Palpation of the M. tensor fasciae latea is very painful, also the palpation of the Mm. glutaeus medius and minimus. There is no resistance, the opposite side is without pathological findings. Standard laboratory whole blood analysis was within normal limits, erythrocyte sedimentation rate (ESR) is 26/52.

1.) What are the most appropriate further investigations?
- Ultrasound of the right hip joint
- Plain radiographs
- CT-Scan of the right hip
- MRI of the right hip joint 

Read more...

 


 

Worldwide News

  • Current Concepts in Joint Replacement™ - Winter 2011

This course will take place in Orlando, Florida, from 7 December to 10 December 2011.

Both hip and knee reconstruction have evolved into mature sciences and are seen to be dependent on a triad of design, patient factors and technical proficiency to achieve clinical longevity. This meeting will focus on both primary and revision outcomes as well as address problems of fixation, bone deficiency, instability, trauma, infection and patient management for hip and knee replacement. Evolving device, material and instrumentation technologies and the recent concerns affecting early in vivo hip and knee performance are addressed. An assemblage of contemporary thought leaders will probe the boundaries of these problems and offer solutions for joint pathologies where arthroplasty is indicated. Plenary commentary, didactic clinical reports, technique videos, debate and case challenges define the formats of presentation, which provide an optimal learning opportunity for orthopaedic surgeons and other allied professionals involved in joint reconstruction. Read more...
Preliminary announcement (pdf)

  • Basic Training
    by Michael Laurence (WOC Newsletter)

May I address some principles of practice which mirror training programs in general? When a patient consults a doctor – or makes a complaint of his or her state of health, he does so with considerable anxiety. He chooses the doctor with the best reputation gleaned from “peer review” from friends, family or better still, other doctors. This reputation will be based upon clinical outcome, how his other patients have done, and how they felt. But fundamentally reputations are lost on mishaps and mistakes. Read more... 

 


 

Industry News

  •  Bayer

 

Xarelto 10 mg film-coated tablets.

(Refer to full SmPC before prescribing.)
Composition: Active ingredient: 10 mg rivaroxaban. Excipients: Microcrystalline cellulose, croscarmellose sodium, lactose monohydrate, hypromellose, sodium laurilsulfate, magnesium stearate, macrogol 3350, titanium dioxide (E171), iron oxide red (E172).Indication: Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery. Contraindications: Hypersensitivity to the active substance or to any of the excipients; clinically significant active bleeding; hepatic disease associated with coagulopathy and clinically relevant bleeding risk; pregnancy and lactation. Warnings and Precautions: not recommended: in patients  concomitantly treated systemically with strong concurrent CYP3A4- and P-gp-inhibitors, i.e. azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors; in patients with severe renal impairment (creatinine clearance <15 ml/min), and due to lack of data in patients below 18 years of age or undergoing hip fracture surgery. Patients at increased risk of bleeding in whom careful monitoring for signs of bleeding complications is required after initiation of treatment: patients with severe renal impairment (creatinine clearance 15 - 29 ml/min) or with moderate renal impairment (creatinine clearance 30 ‑ 49 ml/min) concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations; cirrhotic patients with moderate hepatic impairment (Child Pugh B) not associated with coagulopathy; patients  treated concomitantly with medicinal products affecting haemostasis (such as NSAIDs, acetylsalicylic acid, platelet aggregation inhibitors, other antithrombotic agents); in patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered; patients with congenital or acquired bleeding disorders, uncontrolled severe arterial hypertension, active ulcerative gastrointestinal disease, recent gastrointestinal ulcerations, vascular retinopathy, recent intracranial or intracerebral haemorrhage, intraspinal or intracerebral vascular abnormalities, recent brain, spinal or ophthalmological surgery. Use with caution: in patients treated concomitantly with strong CYP3A4 inducers (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St. John’s Wort) or with the moderate CYP3A4-inhibitor fluconazole. Special care is to be taken when neuraxial anaesthesia or spinal/epidural puncture is employed. Xarelto contains lactose. Undesirable effects: Common: post-procedural haemorrhage (incl. post-operative anaemia, and wound haemorrhage), nausea, fever, peripheral oedema, increased GGT, increase in transaminases (incl. increased ALT, AST). Uncommon: anaemia (incl. respective laboratory parameter), thrombocythaemia (incl. platelet count increased), dizziness, headache, tachycardia, haematoma (incl. rare cases of muscle haemorrhage), gastrointestinal tract haemorrhage (incl. gingival bleeding, rectal haemorrhage, haememesis), urogenital tract haemorrhage, hypotension (incl. blood pressure decreased, procedural hypotension), nose bleed, constipation, diarrhoea, abdominal and gastrointestinal pain (incl. upper abdominal pain, stomach discomfort), dyspepsia (incl. epigastric discomfort), dry mouth, vomiting, pruritus (incl. rare cases of generalised pruritus), rash, contusion, pain in extremity, renal impairment (incl. blood creatinine increased, blood urea increased), localised oedema, decreased general strength and energy (incl. fatigue, asthenia), increase in: lipase, amylase, blood bilirubin, LDH, alkaline phosphatase; wound secretion. Rare: dermatitis allergic, syncope (incl. loss of consciousness), hepatic function abnormal, urticaria (incl. rare cases of generalised urticaria), feeling unwell (incl. malaise), bilirubin conjugated increased (with or without concomitant increased ALT). Frequency not known: hypersensitivity, bleeding into a critical organ (e.g. brain),adrenal haemorrhage, conjunctival haemorrhage, haemoptysis, pseudoaneurysm formation following percutaneous intervention, jaundice, compartment syndrome secondary to a bleeding, renal failure/acute renal failure secondary to a bleeding sufficient to cause hypoperfusion. Classification for supply: Medicinal product subject to medical prescription. 
Special precautions for storage: No special conditions
Date of revision of the text: 4.3.2011
Marketing Authorisation Holder: Bayer Pharma AG, D-13342 Berlin, Germany
Further information available from: Bayer s.r.o., Siemensova 2717/4, 155 00 Prague 5; www.bayer.cz
Version: EU/3.1
  
   

 

Editorial Department
 
Editorial Secretary: Syed Awais
Assistant Editorial Secretary: Hatem Said
Editorial Production: Linda Ridefjord
Special thanks to Anthony Hall
 
Rue Washington 40-b.9, 1050 Brussels, Belgium
Tel.: +32 2 648 68 23 | Fax: +32 2 649 86 01
E-mail: edsecr@sicot.org | Website: www.sicot.org  

 


 

Disclaimer: Some of the views and information expressed in this e-Newsletter include external contributors whose views are not necessarily those of SICOT. SICOT is not responsible for the content of any external internet sites.